The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
- Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the
efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by
subcutaneous (SC) injection, compared with placebo, in patients with IPF
- Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in
North America and Europe
- Randomization: 2:1 active-to-placebo ratio
- Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for
patients who meet predefined criteria)